Bluebird bio Inc

Bluebird bio — Investor Presentation (January 2017)

55 slides from Bluebird bio's investor presentation, Jan 9, 2017

  1. Slide 1: Corporate Overview January 2017

    Corporate Overview January 2017

  2. Slide 2: Forward Looking Statements

    These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expre

  3. Slide 3: Our Vision: Make Hope a Reality

    TRUE BLUE BLUE MOJO OUR PATIENTS OUR PEOPLE OUR VISION: Make Hope a Reality

  4. Slide 4: Our Strategic Intent

    Our Strategic Intent Late Stage (LentiGlobin, Lenti-D) Transformative Product Focus Big Near Term Opportunities (SCD, Multiple Myeloma) “Tetris” R&D (Anti-Pure Play) Best Team (300+) Great Partners Truly Integrated Platform

  5. Slide 5: How Our Gene Therapy Approach Works

    How Our Gene Therapy Approach Works 1 2 3 4 Produce Viral Particle With Therapeutic Payload Isolate Target Cells From Patient Transduce Target Cells ex vivo Test & Re-infuse Gene Modified Cells Targeted Cells Gene Modified Cells Viral Particle

  6. Slide 6: Focused on Building Left & Right Around the Core

    Focused on Building Left & Right Around the Core PIPELINE Learn Innovate Translate GO LEFT PRODUCTS Deliver to Patients GO RIGHT TEAM ATTITUDE BLUEBIRD CORE SCIENCE MANUFACTURING QUALITY COMMERCIAL REGULATORY CLINICAL

  7. Slide 7: bluebird Pipeline Overview

    bluebird Pipeline Overview COLLABORATORS

  8. Slide 8: BLUE Toolbox Strategy

    Good Is Never Good Enough For Patients: BLUE Toolbox Strategy Product Engine Novel areas; autoimmune In vivo gene editing Optimized severe genetic disease products New & enhanced oncology products Transduction Durability BCMA (bb2121) LentiGlobin BCMA & PI3Ki (bb21217) LentiGlobin & Enhancers v1.0 v

  9. Slide 9: Where We Ended 2016

    Where We Ended 2016 Strong momentum across all programs heading into 2017 TDT data & VCN enhancers driving aggressive clinical/regulatory path SCD modifications underway, including strong start with VCN enhancers Exciting (early) multiple myeloma BCMA data Significant growth while maintaining our cu

  10. Slide 10: How Do We Get There? Data, Execution and Development in 2017

    How Do We Get There? Data, Execution and Development in 2017 LentiGlobin, TDT and SCD Update @ ASH LentiGlobin, TDT Update @ EHA CRB-401 Study Data (bb2121) @ ASCO DATA EXECUTION Initiate HGB-212 Study of LentiGlobin Confirm LentiD, CALD Clinical/ Regulatory Path Preparations for TDT EU MAA Filing F

  11. Slide 11: Context for 2017

    MM TDT SCD CALD Context for 2017

  12. Slide 12: The Gene Therapy Product Company

    T H E G E N E T H E R A P Y P R O D U C T C O M P A N Y Products on the Market Programs Nearing Commercialization Additional Programs in the Clinic 2+ 4+ 2+ Patient Impact ∞ World-class Gene Therapy Platform and Integrated Global Capabilities

  13. Slide 13: Program Summaries

    Program Summaries

  14. Slide 14: bb2121 Current Status

    bb2121 Current Status Preliminary results suggest bb2121 demonstrated objective responses in heavily pretreated patients with multiple myeloma Patients in the second cohort achieved stringent complete responses and/or elimination of minimal residual disease 100% ORR (6/6) with doses above 5x107 CAR+

  15. Slide 15: LentiGlobin Current Status: TDT

    LentiGlobin Current Status: TDT* LentiGlobin treatment shows promising results in TDT Patients with non-β0/β0 genotypes and ≥12 months follow-up remain free of RBC transfusions Clinically meaningful reductions in transfusion volume and frequency in patients with β0/β0 genotypes Toxicity profile rema

  16. Slide 16: LentiGlobin Current Status: Severe SCD

    LentiGlobin Current Status: Severe SCD Results in HGB-205 subject 1204 demonstrate promise of LentiGlobin autologous gene therapy for severe SCD ~50% anti-sickling hemoglobin with sustained absence of severe sickle cell disease-related symptoms Initial findings from HGB-206 confirm feasibility of au

  17. Slide 17: Lenti-D Current Status

    Lenti-D Current Status Initial interim Starbeam results suggest early treatment with Lenti-D gene therapy may halt neuro-inflammation and demyelination in most CALD patients, with promising safety All subjects were free of Major Functional Disabilities (MFD) as of March 31, 2016 data cut-off Stabili

  18. Slide 18: Multiple Myeloma

    Multiple Myeloma

  19. Slide 19: bb2121: Anti-BCMA Chimeric Antigen Receptor T Cell Product Candidate

    Autologous T cells transduced with a lentiviral vector encoding a novel anti-BCMA CAR 4-1BB co-signaling motif selected to promote proliferation and persistence Construct demonstrated potent preclinical in vivo activity with low tonic signaling anti-BCMA CAR design bb2121 demonstrates low antigen-in

  20. Slide 20: CRB-401 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

    CRB-401 Phase 1 Study in Relapsed / Refractory Multiple Myeloma Objectives: Determine preliminary safety and efficacy and recommended phase 2 dose N = 50 patients, standard 3+3 dose escalation + expansion cohort Eligibility Relapsed / refractory MM with ≥ 3 prior lines of therapy (including PI and I

  21. Slide 21: Study Status as of November 18, 2016

    Study Status as of November 18, 2016 BCMA+ cells (% of CD138+ plasma cells) <10% 10–25% 26–49% ≥ 50% ≥ 50% Consented N=19 Cells Collected N=13 Dosed N=11 Not eligible N=6 In process N=1 Clinical deterioration prior to infusion N=1 1 Month Response Evaluation N=9 60% of pre-screened patients (n=75) h

  22. Slide 22: Demographics and Disease History in Treated Patients

    Demographics and Disease History in Treated Patients Parameter Statistic N=11 Dosed Patients Age years Median (range) 58 (41-74) Male gender N (%) 7 (64%) Time since diagnosis years Median (range) 5 (1-9) ECOG1 = 0 N (%) 6 (55%) ISS2 Stage I II III N (%) 5 (45%) 4 (36%) 2 (18%) High-risk cytogenetic

  23. Slide 23: Adverse Events Generally Mild

    Adverse Events Generally Mild, No ≥ Grade 3 CRS* or Neurotoxicity No dose-limiting toxicities as of data cut-off Cytopenias related to fludarabine/ cyclophosphamide lymphodepletion, as expected No ≥ Grade 3 cytokine release syndrome or neurotoxicity as of data cut-off n Treatment Emergent Adverse Ev

  24. Slide 24: Best Response and Time Since bb2121 Infusion

    Best Response and Time Since bb2121 Infusion † † PR PR PR VGPR sCR Best response to date sCR PD SD PR 45x107 15x107 5x107 * * * * Dose CAR+ T cells MRD negative Best response First response Disease progression Death † Data as of Nov 18, 2016 * Patient with ≥50% bone marrow involvement

  25. Slide 25: Responses to bb2121 Infusion

    Responses to bb2121 Infusion Baseline Day 14 All patients treated at doses > 5x107 with bone marrow involvement at baseline have had no detectable bone marrow disease on Day 14 or beyond Baseline Month 1 Serum M-protein dFLC (% change from baseline)* CD138 BCMA IHC PET Bone marrow response and tumor

  26. Slide 26: CAR T Cell Expansion at Every Dose

    CAR T Cell Expansion at Every Dose Vector Copies in CD3-enriched Peripheral Blood by PCR Decrease in Serum BCMA Correlated with CAR T Expansion LLOQ CAR+ T cells in Bone Marrow @ D14 by FLOW Comp-PE-A :: rhBCMA Comp-APC-A :: CD3 68% bb2121 CAR T cells Data as of Nov 18, 2016

  27. Slide 27: Cytokine Release Syndrome Summary

    Cytokine Release Syndrome Summary 8/11 (73%) with cytokine release syndrome (CRS) CRS severity Grades 1 & 2 Including patients in all dose groups and those with ≥50% bone marrow involvement CRS-related symptoms mostly Grade 1 No patients received tocilizumab or steroids Reported CRS-Related Symptoms

  28. Slide 28: Transfusion Dependent β-Thalassemia

    Transfusion Dependent β-Thalassemia

  29. Slide 29: TDT Studies: Status

    TDT Studies: Status HGB-204 multicenter study of LentiGlobin in TDT CURRENT STATUS HGB-205 single center study of LentiGlobin in TDT and severe SCD CURRENT STATUS All 18 patients treated, with ≥ 6 months follow-up 2 patients have completed 2-year analysis 4 TDT patients treated, with 11 – 33 months

  30. Slide 30: Patient and Drug Product Characteristics HGB-204

    Patient and Drug Product Characteristics HGB-204 N=18 treated patients Genotype β0/β0 (n=8) Non-β0/β0 (n=10) Genotype 8 10 βE/β0 -- 6 Other (β+/β0, β+/β+, βx/β0) -- 4 Age at start of regular transfusions Age at consent Median (range) years 0 (0 – 7) 23 (12 - 35) 6 (0 – 26) 19.5 (16 – 34) Median (ran

  31. Slide 31: Patient and Drug Product Characteristics HGB-205

    Patient and Drug Product Characteristics HGB-205 1201 1202 1203 1206 Age at Enrollment (years) 18 16 19 17 Genotype β0/βE β0/βE homozygous IVS1 nt 110 G>A β0/βE Pre-Treatment pRBC Transfusions (mL/kg/year)1 139 188 176 197 VCN in Drug Product2 1.5 2.1 0.8 1.1 CD34+ Cell Dose (x106/kg) 8.9 13.6 8.8 1

  32. Slide 32: HbAT87Q production increases to month 9, then stabilizes

    HbAT87Q production increases to month 9, then stabilizes 204 other genotype 204 β0/β0 genotype 205 other genotype Data as of Sept 9, 2016 [HGB-205], Sept 16, 2016 [HGB-204]

  33. Slide 33: Peripheral VCN correlates with DP VCN and HbAT87Q level

    Peripheral VCN correlates with DP VCN and HbAT87Q level at Month 6 R2 = 0.72 P<0.0001 R2: 0.38 P ≤ 0.01 Peripheral VCN vs. DP VCN HbAT87Q vs. Peripheral VCN Data as of Sept 16, 2016

  34. Slide 34: Non-β0/β0 patients with ≥12 months follow-up have stopped RBC transfusions

    Patients with non-β0/β0 genotypes and ≥12 months follow-up have stopped RBC transfusions Time from treatment to last transfusion Time since last transfusion Total Hb (g/dL) @ last study visit 10.9 13.5 8.3 11.3 9.5 10.3 11.7 12.3 12.5 10.3 7.2 9.1 9.0 11.3 months Data as of Sept 9, 2016 [HGB-205], S

  35. Slide 35: Transfusion reduction seen in β0/β0 patients

    Transfusion reduction seen in patients with β0/β0 genotypes with ≥12 months follow-up 65% Median Reduction in Transfusion Number (range 31%-81%) 63% Median Reduction in Transfusion Volume (range 47%-78%) Transfusion Volume Number of Transfusions Data as of Sept 16, 2016 Post-treatment: annualized on

  36. Slide 36: Research-Scale Results Demonstrate Increase in Drug Product VCN

    Other genotypes β0/β0 genotypes HGB-207 first patient Data as of Nov 30, 2016 Exploratory in vitro analysis conducted at research scale 2.9 no enhancement transduction enhancement Percent of cells transduced: 77% Research-scale Results Demonstrate Increase in Drug Product VCN Across Genotypes

  37. Slide 37: Next Steps: Pivotal Studies HGB-207 and HGB-212

    HGB-207 Non-β0/β0 genotypes HGB-212 β0/β0 genotypes Phase 3, multi-center, global study Phase 3, multi-center, global study N=15 adults and adolescents, and N=8 pediatric patients Open and enrolling N=15 adults, adolescents and pediatric patients Initiation planned for 2017 Next steps: Pivotal clini

  38. Slide 38: U.S. Registration Strategy

    U.S. Registration Strategy General agreement with U.S. regulators on the registration path for LentiGlobin BB305 for the treatment of transfusion-dependent β-thalassemia U.S. Pursue approval in adults and adolescents based on data from ongoing pivotal HGB-207 trial Pediatric population to be include

  39. Slide 39: EU Registration Strategy

    EU Registration Strategy General agreement with EU regulators on the registration path for LentiGlobin BB305 for the treatment of transfusion-dependent β-thalassemia EU Pursue CONDITIONAL APPROVAL on the basis of data from ongoing HGB-204 (Northstar) & HGB-205 studies ADAPTIVE PATHWAYS Plan to inclu

  40. Slide 40: Sickle Cell Disease

    Sickle Cell Disease

  41. Slide 41: Current Status of HGB-206 Study

    Current Status of HGB-206 Study As of November 9, 2016 Enrollment criteria 18+ years of age History of symptomatic SCD Adequate organ function/performance status No previous HSCT or gene therapy Target: up to 29 treated subjects Ineligible/withdrew consent N=3* Bone Marrow Harvest planned or in prog

  42. Slide 42: Patient and Treatment Characteristics

    Patient and Treatment Characteristics Treatment Characteristics Parameter HGB-206 (n=7) Median (range) HGB-205 (n=1) Age at Enrollment (years) 26 (18 – 42) 13 Bone Marrow Harvests 2 (1 – 4) 2 Target daily busulfan AUC (μM/min) 5000 (4400 – 5400) 4841 (actual) LentiGlobin DP cell dose (CD34+x106 cell

  43. Slide 43: Vector Copy Number in Drug Product and Peripheral Blood

    Vector Copy Number (VCN) in Drug Product and Peripheral Blood Vector copy number (VCN; per diploid genome) VCN drop from drug product to peripheral blood in HGB-206 Peripheral blood VCN over time 1204 Data as of Sept 9, 2016 [HGB-205] and Nov 9, 2016 [HGB-206]

  44. Slide 44: All Treated Patients Produce Measurable HbAT87Q

    All Treated Patients Produce Measurable HbAT87Q Data as of Sept 9, 2016 [HGB-205] and Nov 9, 2016 [HGB-206]

  45. Slide 45: 8% to 48% Anti-Sickling Hemoglobin at Last Follow Up

    12 12 9 9 6 6 9 48% Anti-Sickling Hb 30.0% 14.2% 18.3% 22.8% 16.5% 7.9% 21 18.7% 1301 1303 1304 1306 1308 1309 1310 1204 12 12 9 9 6 9 6 21 Follow up (Months) Data as of Sept 9, 2016 [HGB-205] and Nov 9, 2016 [HGB-206] 8% to 48% Anti-Sickling Hemoglobin at Last Follow Up

  46. Slide 46: Clinical Outcomes 21 Months After Treatment in HGB-205 Patient 1204

    Chronic transfusions Weaned off transfusions Last transfusion on Day + 88 (> 18 months ago) Multiple hospitalizations before starting transfusion regimen No hospitalizations or acute SCD-related events Baseline while on transfusions Reticulocytes 238.3 x 109/L LDH 626 U/L Bilirubin 50 μmol/L Reticul

  47. Slide 47: Interim Summary – Where are we today?

    Interim Summary – Where are we today? Results in HGB-205 subject 1204 demonstrate promise of LentiGlobin autologous gene therapy for severe SCD ~50% anti-sickling hemoglobin with sustained absence of severe sickle cell disease-related symptoms Initial findings from HGB-206 confirm feasibility of aut

  48. Slide 48: Stem Cell Transduction and Engraftment – The Challenge of SCD

    Stem Cell Transduction and Engraftment – The Challenge of Sickle Cell Disease Adequate myeloablation Successful engraftment of transduced cells Healthy bone marrow Robust HSC harvest Effective transduction Receptive marrow niche High transduced cell dose Persistent, expanding transduced HSCs Low tra

  49. Slide 49: Protocol and Process Changes to Potentially Improve Outcomes in SCD

    Protocol and Process Changes to Potentially Improve Outcomes in SCD Patients Hypoxic, inflamed marrow Pre-harvest transfusions to reduce marrow inflammation, hypoxia Low yield harvest Additional changes to manufacturing process to increase cell dose Poor transduction VCN Enhancers (Process 2) Inadeq

  50. Slide 50: Manufacturing Process with Transduction Enhancers Increases DP VCN

    LentiGlobin Manufacturing Process with Transduction Enhancers Increases DP VCN in SCD CD34+ Cells 1 2 3 4 5 6 7 8 9 10 11 12 13 HGB-206 drug product Research-scale SCD patient CD34+ cells transduced Data as of Nov 30, 2016 Percent of cells transduced: 83% 3.3 no enhancement transduction enhancement

  51. Slide 51: Nasdaq : BLUE

    Nasdaq : BLUE

  52. Slide 52: The 2017 Plan is Clear and Catalyst Rich

    The 2017 Plan is Clear and Catalyst Rich Data from HGB-207 & Initiate HGB-212 Ongoing Data from HGB 204 & 205 VCN Enhancers Impact & Filing Strategy β-THALASSEMIA HGB-206 HGB-205 Protocol & VCN Enhancers Impact SICKLE CELL DISEASE Allo Transplant Study Starbeam Study Expansion Confirm Regulatory Str

  53. Slide 53: 2022 Vision – The Gene Therapy Product Platform

    Products on the Market Programs Nearing Commercialization Additional Programs in the Clinic 2+ 4+ 2+ Patient Impact ∞ 2022 Vision – The Gene Therapy Product Platform

  54. Slide 54: 2022 – We Must Make Hope a Reality

    2022 – We Must Make Hope a Reality Bringing & Valuing Hope Go TRUE BLUE

  55. Slide 55: Closing

    Closing Nick Leschly, chief bluebird

bluebird bio — Investor Presentation (January 2017) on 6ix